<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02085265</url>
  </required_header>
  <id_info>
    <org_study_id>148-2013</org_study_id>
    <nct_id>NCT02085265</nct_id>
  </id_info>
  <brief_title>Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients</brief_title>
  <acronym>SARTAN-AD</acronym>
  <official_title>The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimerâ€™s Drug Discovery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weston Brain Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To conduct a proof of concept study in patients with mild to moderate Alzheimer's Disease in
      order to determine if there is less global brain atrophy over one year, as measured by
      ventricular enlargement as a primary outcome measure, when patients are randomized to
      treatment with an angiotensin receptor blocker (ARB) compared to an angiotensin converting
      enzyme inhibitor (ACEI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study uses a simple validated measure of brain atrophy as a surrogate marker in a
      repurposing effort that could recast an antihypertensive medication as a cognitive
      enhancer/neuroprotective agent and possibly as a drug of choice for Alzheimer patients and
      patients at risk for AD. If the proof of concept result is positive, a larger study would be
      warranted with potential practice-changing impact.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventricular enlargement</measure>
    <time_frame>12 months</time_frame>
    <description>Change in ventricular size, on 3D T1 MR imaging, after 12 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Change in blood pressure (BP) measurements after 12 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Vital signs</measure>
    <time_frame>12 months</time_frame>
    <description>Change in vital sign (heart rate, pulse) measurements after 12 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Electrolytes</measure>
    <time_frame>12 months</time_frame>
    <description>Change in electrolyte measurements (Na, K) after 12 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events and serious adverse events over 12 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hippocampal volume</measure>
    <time_frame>12 months</time_frame>
    <description>Change in hippocampal volume measurements after 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grey/White matter volume</measure>
    <time_frame>12 months</time_frame>
    <description>Volume of grey and white matter in the cingulate, parietotemporal and dorsolateral frontal regions after 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive and functional measures</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Determine comparative efficacy of perindopril vs. telmisartan on cognitive and functional measures and on other structural brain imaging measures in this participant population</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Neuropsychiatric Measures</measure>
    <time_frame>6 &amp; 12 months</time_frame>
    <description>Assess the comparative treatment responsiveness of neuropsychiatric measures and obtain pilot data</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment responsiveness of Diffusion Tensor Imaging (DTI)</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the comparative treatment responsiveness of Diffusion Tensor Imaging (DTI) and obtain pilot data</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment responsiveness of resting state functional MRI (rsfMRI)</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the comparative treatment responsiveness of multi-modal MRI, resting-state functional MRI (rsfMRI) and arterial spin labeling (in a subset of participants) and obtain pilot data.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life - Caregiver burden</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the comparative response of caregiver burden after treatment using Zarit burden interview.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life - Health-related</measure>
    <time_frame>12 months</time_frame>
    <description>Assess health related quality of life after treatment using EQ-5D-5L questionnaire.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perindopril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril</intervention_name>
    <description>Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)</description>
    <arm_group_label>Perindopril</arm_group_label>
    <other_name>Coversyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)</description>
    <arm_group_label>Telmisartan</arm_group_label>
    <other_name>Micardis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Diagnosis of Probable AD dementia or Possible AD dementia due to concomitant
             cerebrovascular disease (as permitted by the study exclusion criteria), using the 2011
             McKhann criteria.

          2. Previous brain MRI or CT scan to rule out exclusionary pathology, and absence of
             stepwise decline since the previous scan.

          3. Age 50 years or older

          4. Standardized Mini Mental State Examination (SMMSE) score of 16-27 at screening visit

          5. Sufficient hearing and vision to participate in testing as per investigator's
             judgement

          6. Sufficient fluency in English to understand instructions and to be able to complete
             SMMSE

          7. At least 8 years of education

          8. A study partner who in the opinion of the study investigator has regular interaction
             with the participant, can be present for study visits, can provide a collateral
             history and can ensure compliance with study procedures

          9. HbA1C &lt;8.5%. Patients with stable type II diabetes are eligible for the study if there
             have been no severe hypoglycemic events requiring third party intervention (e.g.
             emergency department visit) for 6 months prior to randomization

         10. Patients on cholinesterase inhibitors or memantine, medications for vascular risk
             factors (e.g., hypertension, cholesterol, diabetes), or on psychotropic medications
             must be on a stable dose for 30 days prior to randomization.

        Exclusion criteria

          1. Intolerance, or any contraindications, to study medications

          2. Average SBP &lt;110mmHg or average DBP &lt;60 mmHg during screening

          3. Familial autosomal dominant form of Alzheimer's disease

          4. Creatinine clearance less than or equal to 30ml/min

          5. Serum potassium &gt; 5.5 mEq/L

          6. ALT 3x &gt; the upper limit of normal (ULN)

          7. History of angioedema

          8. Co-morbid acute or chronic conditions (including type I diabetes mellitus, other
             neurological conditions such as Parkinson's disease, psychiatric disorders, and severe
             or unstable medical conditions) that could confound assessments or would, in the
             judgment of the investigator, make the subject inappropriate for entry into this study

          9. Any of the following findings on previous CT/MRI or on screening MRI:

             Brain Location: Anywhere, Exclusionary Finding: Malignant tumour, Size: Any, Excl. #:
             Any

             Brain Location: Anywhere, Exclusionary Finding: Tumour w/ sig. mass effect, Size:
             Sufficient for mass effect, Excl. #: Any

             Brain Location: Anywhere, Exclusionary Finding: Vascular malformations, Size: Any,
             Excl. #: Any

             Brain Location: Anywhere, Exclusionary Finding: Subdural hematoma, Size: Any, Excl. #:
             Any

             Brain Location: Anywhere, Exclusionary Finding: Intracerebral hemorrhage, Size: Any,
             Excl. #: Any

             Brain Location: Anywhere, Exclusionary Finding: Cerebral microbleeds, Size: Any, Excl.
             #: more than 5

             Brain Location: Cortex, Exclusionary Finding: Superficial siderosis, Size: Any, Excl.
             #: more than 1 instance of focal SS

             Brain Location: Cortex, Exclusionary Finding: Ischemic infarct, Size: &gt;1.5 cm in
             diameter, Excl. #: Any

             Brain Location: Cortex, Exclusionary Finding: Ischemic infarct, Size: â‰¤1.5 cm in
             diameter, Excl. #: more than 1

             Brain Location: Periventricular Exclusionary Finding: Fazekas score 3 with White
             matter hyperintensity band along the lateral surface of the ventricles, Size: &gt;0.5 cm
             in width Excl. #: Any

             Brain Location: White matter, Exclusionary Finding:Ischemic infarct, Size: &gt;1.5 cm in
             diameter, Excl. #:Any

             Brain Location: White matter, Exclusionary Finding: Ischemic infarct, Size: 1.0-1.5 cm
             in diameter, Excl. #: more than 2

             Brain Location: Basal ganglia, Exclusionary Finding: Ischemic infarct, Size: &gt;1.0 cm
             in diameter, Excl. #: Any

             Brain Location: Basal ganglia and white matter, Exclusionary Finding: Ischemic
             infarct, Size: â‰¤1.0 cm in diameter, Excl. #: more than 4

             Brain Location: Thalamus, Exclusionary Finding: Strategic infarct, Size: Any, Excl. #:
             Any

             Brain Location: Hippocampus, Exclusionary Finding: Strategic infarct, Size: Any,
             Excl#.: Any

         10. Inability to perform the study procedures, including claustrophobia or
             contraindications for MRI

         11. Currently on or has taken an angiotensin receptor blocker within 12 months of
             randomization visit

         12. Resides in a nursing home (participants who reside in retirement homes may be included
             if they have a study partner who meets inclusion criterion #8)

         13. Current major depression by clinical history or score greater than 18 on the Cornell
             Scale for Depression in Dementia

         14. Documented potential cardiac source of brain infarction such as mechanical valve or
             atrial fibrillation that is untreated or treated with warfarin or an antiplatelet
             agent; atrial fibrillation treated with a novel oral anticoagulant is permitted, as is
             a history of remote, transient atrial fibrillation that has not recurred
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Black, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krista Lanctot, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Black, MD</last_name>
    <phone>416.480.4551</phone>
    <email>sandra.black@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ljubica Zotovic, MD</last_name>
    <phone>416.480.6100</phone>
    <phone_ext>3004</phone_ext>
    <email>ljubica.zotovic@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Charlton</last_name>
      <phone>403-210-6164</phone>
      <email>acharlto@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Eric Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Lethbridge</name>
      <address>
        <city>Lethbridge</city>
        <state>Alberta</state>
        <zip>T1K 6T5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Kennedy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Sutherland, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mannie Fan</last_name>
      <phone>604-822-0550</phone>
      <email>mannie.fan@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Robin Hsiung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuhira Himed</last_name>
      <phone>905.521.2100</phone>
      <phone_ext>44468</phone_ext>
      <email>himed@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Demetrios (James) Sahlas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkwood Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 4R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Shostak</last_name>
      <phone>519-685-4292</phone>
      <phone_ext>45609</phone_ext>
      <email>rebecca.shostak@sjhc.london.on.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Borrie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Memory and Aging</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karan Patel</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>7432</phone_ext>
      <email>karan.patel@sri.utoronto.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ljubica Zotovic</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>3004</phone_ext>
      <email>ljubica.zotovic@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sandra Black, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Corinne Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baycrest Health Sciences</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naga Avvaru</last_name>
      <phone>(416) 785-2500</phone>
      <phone_ext>3627</phone_ext>
      <email>navvaru@research.baycrest.org</email>
    </contact>
    <investigator>
      <last_name>Howard Chertkow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Chan</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>30939</phone_ext>
      <email>claire.chan@camh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Shima Ovaysikia</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>32589</phone_ext>
      <email>Lina.Chiuccariello@camh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjeev Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 29, 2013</study_first_submitted>
  <study_first_submitted_qc>March 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2014</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Sandra E Black</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Perindopril</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>Brain atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

